tbuckley/cabot-search huggingface dataset:
Emotional competence self-help app versus cognitive behavioural self-help app versus self-monitoring app to prevent depression in young adults with elevated risk (ECoWeB PREVENT): an international, multicentre, parallel, open-label, randomised controlled trial
Authors: Edward R Watkins, Fiona C Warren, Alexandra Newbold, Claire Hulme, Timothy Cranston, Benjamin Aas, Holly Bear, Cristina Botella, Felix Burkhardt, Thomas Ehring, Mina Fazel, Johnny R J Fontaine, Mads Frost, Azucena Garcia-Palacios, Ellen Greimel, Christiane Hößle, Arpine Hovasapian, Veerle E I Huyghe, Kostas Karpouzis, Johanna Löchner, Guadalupe Molinari, Reinhard Pekrun, Belinda Platt, Tabea Rosenkranz, Klaus R Scherer, Katja Schlegel, Bjorn W Schuller, Gerd Schulte-Korne, Carlos Suso-Ribera, Varinka Voigt, Maria Voß, Rod S Taylor
Journal: The Lancet Digital Health (2024)
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1
Authors: Richard M Bergenstal, Björg Ásbjörnsdóttir, Sara K Watt, Ildiko Lingvay, Julia K Mader, Tomoyuki Nishida, Julio Rosenstock
Journal: The Lancet Diabetes & Endocrinology (2024)
Neoplastic progression risk in females with Barrett’s esophagus: a systematic review and meta-analysis of individual patient data
Authors: Pauline A Zellenrath, Laurelle van Tilburg, Roos E Pouw, Rena Yadlapati, Yonne Peters, Michael B Ujiki, Prashanthi N Thota, Norihisa Ishimura, Stephen J Meltzer, Noam Peleg, Won-Tak Choi, John V Reynolds, Alexandros D Polydorides, Arjun D Koch, Judith Honing, Manon C W Spaander
Journal: Clinical Gastroenterology and Hepatology (2024)

Females with Barrett's esophagus (BE) have a lower risk of neoplastic progression than males, but sufficiently powered risk analyses are lacking. This systematic review and meta-analysis of individual patient data (IPD) aimed to provide more robust evidence on neoplastic progression risk in females.
Environmental risk factors for gallbladder cancer: field-wide systematic review and meta-analysis.
Authors: Daniele Piovani, Georgios K Nikolopoulos, Alessio Aghemo, Ana Lleo, Saleh A Alqahtani, Cesare Hassan, Alessandro Repici, Stefanos Bonovas
Journal: Clinical Gastroenterology and Hepatology (2024)

Cholelithiasis is the most well-recognized risk factor for gallbladder cancer (GBC), the predominant biliary-tract malignancy; however, credibility on other modifiable exposures remains uncertain. We performed a field-wide systematic review and meta-analysis on environmental factors associated with GBC.
A novel SARS-CoV-2 recombinant transmitted from a patient with an acute co-infection
Authors: Robert Dyrdak, Sofia Stamouli, Shambhu Ganeshappa Aralaguppe, Martin Ekman, Hamzah Safari, Carlo Berg, Elin Movert, Neus Latorre-Margalef, Emmi Andersson, Magnus Gisslén, Joanna Nederby-Öhd, Åsa Sjödin Leufvén, Josette Schoenmakers, Sandra Broddesson, Ben Murrell, Jan Albert
Journal: The Lancet Microbe (2024)
Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma
Authors: Erdong Wei, Ana Mitanoska, Quinn O'Brien, Kendall Porter, MacKenzie Molina, Haseeb Ahsan, Usuk Jung, Lauren Mills, Michael Kyba, Darko Bosnakovski
Journal: Molecular Cancer (2024)
Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia
Authors: Qiaoyu Pan, Xiaofei Xin, Sohan Mahto, Yuxiang Dong, Virender Kumar, R Katherine Hyde, Neha Gupta, Vijaya R Bhatt, Ram I Mahato
Journal: Molecular Therapy (2024)
Engineered Extracellular Vesicles for Combinatorial TNBC Therapy: SR-SIM-Guided Design Achieves Substantial Drug Dosage Reduction
Authors: Abhjeet S Bhullar, Kai Jin, Haizhu Shi, Austen Jones, Dalton Hironaka, Gaofeng Xiong, Ren Xu, Peixuan Guo, Daniel W Binzel, Dan Shu
Journal: Molecular Therapy (2024)
Associations between vision impairment and eye diseases with dementia, dementia subtypes and cognitive impairment: An umbrella review
Authors: Masoud Rahmati, Lee Smith, Hyeri Lee, Laurent Boyer, Guillaume Fond, Dong Keon Yon, Hayeon Lee, Pinar Soysal, Raphael Udeh, Xenia Dolja-Gore, Mark McEVoy, Mapa Prabhath Piyasena, Shahina Pardhan
Journal: Ageing Research Reviews (2024)
Removing Interoceptive Input from the Kidney to the Brain Reduces Salt Appetite in DOCA Hypertensive Rats.
Authors: Mariana R Lauar, Rawan N Almutlaq, Sridhatri Guntipally, Babatunde Anidu, Rachel Kram, Jaryd Ross, John W Osborn, Alex Dayton, Louise C Evans
Journal: Kidney International (2024)
The Lancet Psychiatry Commission on mental health in Ukraine
Authors: Irina Pinchuk, Bennett L Leventhal, Alisa Ladyk-Bryzghalova, Lars Lien, Yuliia Yachnik, Marisa Casanova Dias, Volodymyr Virchenko, Peter Szatmari, Olena Protsenko, Gary Andrew Chaimowitz, Dan Chisholm, Viktoriia Kolokolova, Anthony P S Guerrero, Stanislav Chumak, Olha Myshakivska, Paul Gerard Robertson, Mark D Hanson, Howard Yee Liu, Livia Joanna De Picker, Marina Kupchik, Mariana Pinto da Costa, James G Scott, Milton Leonard Wainberg, Lidiya Shevaga, Rebecca Weintraub Brendel, Robert van Voren, Inna Feldman, Cathy Mihalopoulos, Svitlana Kaminska, Norbert Skokauskas
Journal: The Lancet Psychiatry (2024)
Emotional competence self-help mobile phone app versus cognitive behavioural self-help app versus self-monitoring app to promote mental wellbeing in healthy young adults (ECoWeB PROMOTE): an international, multicentre, parallel, open-label, randomised controlled trial
Authors: Edward R Watkins, Fiona C Warren, Alexandra Newbold, Claire Hulme, Timothy Cranston, Benjamin Aas, Holly Bear, Cristina Botella, Felix Burkhardt, Thomas Ehring, Mina Fazel, Johnny R J Fontaine, Mads Frost, Azucena Garcia-Palacios, Ellen Greimel, Christiane Hößle, Arpine Hovasapian, Veerle E I Huyghe, Kostas Karpouzis, Johanna Löchner, Guadalupe Molinari, Reinhard Pekrun, Belinda Platt, Tabea Rosenkranz, Klaus R Scherer, Katja Schlegel, Bjorn W Schuller, Gerd Schulte-Korne, Carlos Suso-Ribera, Varinka Voigt, Maria Voß, Rod S Taylor
Journal: The Lancet Digital Health (2024)

Based on evidence that mental health is more than an absence of mental disorders, there have been calls to find ways to promote flourishing at a population level, especially in young people, which requires effective and scalable interventions. Despite their potential for scalability, few mental wellbeing apps have been rigorously tested in high-powered trials, derived from models of healthy emotional functioning, or tailored to individual profiles. We aimed to test a personalised emotional competence self-help app versus a cognitive behavioural therapy (CBT) self-help app versus a self-monitoring app to promote mental wellbeing in healthy young people.
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
Authors: Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, Andrew Martin, Anthony Jaworski, Niall Tebbutt, Yung-Jue Bang, Thierry Alcindor, Chris O'Callaghan, Andrew Strickland, Sun Young Rha, Keun-Wook Lee, Jin-Soo Kim, Li-Yuan Bai, Hiroki Hara, Do-Youn Oh, Sonia Yip, John Zalcberg, Tim Price, John Simes, David Goldstein
Journal: Journal of Clinical Oncology (2024)

PURPOSE Treatment options for refractory advanced gastric and esophagogastric junction cancer (AGOC) are limited. Regorafenib, an oral multikinase inhibitor, prolonged progression-free survival (PFS) versus placebo in the INTEGRATE I phase II trial. INTEGRATE IIa was designed to examine whether regorafenib improved overall survival (OS). METHODS A double-blind placebo-controlled phase III trial compared regorafenib and best supportive care (BSC) versus placebo and BSC for participants with confirmed evaluable metastatic/advanced AGOC who failed ≥two prior therapies on a 2:1 random assignment, stratified by tumor location, geographic region (Asia v rest of world), and prior vascular endothelial growth factor inhibitors. The primary end point was OS. Treatment efficacy on OS was first tested in the pooled INTEGRATE I + INTEGRATE IIa cohort and, if significant, then in the INTEGRATE IIa cohort. Secondary end points were PFS, objective response rate, safety, and quality of life (QoL). RESULTS INTEGRATE IIa enrolled 251 participants: 157 from Asia and 94 from rest of world and 169 received regorafenib and 82 received placebo. No significant heterogeneity was observed between INTEGRATE I and INTEGRATE IIa studies on OS. Pooled OS analysis hazard ratio (HR) was 0.70 (95% CI, 0.56 to 0.87; P = .001; 361 events). INTEGRATE IIa alone OS HR was 0.68 (95% CI, 0.52 to 0.90; P = .006; 238 events), the median OS was 4.5 months versus 4.0 months, and 12-month survival rates were 19% and 6%, for regorafenib versus placebo, respectively. After a preplanned adjustment for multiplicity, there were no statistically significant differences across regions or other prespecified subgroups. Regorafenib improved PFS (HR, 0.53 [95% CI, 0.40 to 0.70]; P &lt; .0001) and delayed deterioration in global QoL (HR, 0.68 [95% CI, 0.52 to 0.89]; P = .0043). The toxicity profile was consistent with that of previous reports. CONCLUSION Regorafenib improves survival compared with placebo in refractory AGOC.
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup> F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
Authors: Feng-Ming (Spring) Kong, Chen Hu, Daniel A. Pryma, Fenghai Duan, Martha Matuszak, Ying Xiao, Randall Ten Haken, Marilyn J. Siegel, Lucy Hanna, Walter J. Curran, Mark Dunphy, Daphna Gelblum, Morand Piert, Shruti Jolly, Clifford G. Robinson, Andrew Quon, Billy W. Loo, Shyam Srinivas, Gregory M. Videtic, Sergio L. Faria, Catherine Ferguson, Neal E. Dunlap, Vijayananda Kundapur, Rebecca Paulus, Barry A. Siegel, Jeffrey D. Bradley, Mitchell Machtay
Journal: Journal of Clinical Oncology (2024)

PURPOSE NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428 ), a randomized phase II trial, studied whether midtreatment 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease. MATERIALS AND METHODS Patients fit for concurrent chemoradiation were randomly assigned (1:2) to standard (60 Gy/30 fractions) or FDG-PET–guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z -test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUV peak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression. RESULTS Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P = .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival ( P &gt; .4). Median SUV peak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, ΔSUV peak and ΔMTV were not associated with FFLP (hazard ratios, 0.997; P = .395 and .461). CONCLUSION Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
Authors: Michael R. Sargen, Raymond L. Barnhill, David E. Elder, Susan M. Swetter, Victor G. Prieto, Jennifer S. Ko, Armita Bahrami, Pedram Gerami, Arivarasan Karunamurthy, Alberto S. Pappo, Lynn M. Schuchter, Philip E. LeBoit, Iwei Yeh, John M. Kirkwood, Melinda Jen, Ira J. Dunkel, Megan M. Durham, Emily R. Christison-Lagay, Mary T. Austin, Jennifer H. Aldrink, Casey Mehrhoff, Elena B. Hawryluk, Emily Y. Chu, Klaus J. Busam, Vernon Sondak, Jane Messina, Susana Puig, Andrew J. Colebatch, Carrie C. Coughlin, Kristen G. Berrebi, Theodore W. Laetsch, Sarah G. Mitchell, Brittani Seynnaeve
Journal: Journal of Clinical Oncology (2024)

PURPOSE The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients. METHODS A Children's Oncology Group–led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise. RESULTS Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications. RECOMMENDATIONS (1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.
Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes
Authors: Dawn Owen, Christina Hunter Chapman
Journal: Journal of Clinical Oncology (2024)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
The UN Decade of Healthy Ageing (2021–30) for people living with HIV
Authors: Giovanni Guaraldi, Jovana Milic, Eduardo Gnoatto Perondi, Ana Catarina Rodrigues Gonçalves, Cristina Mussini, Marco Antonio de Avila Vitoria, Matteo Cesari
Journal: The Lancet Healthy Longevity (2024)

The Decade of Healthy Ageing (2021-30; the Decade), proclaimed by the UN in 2020, is a global initiative aimed at fostering collaborations to transform the world into a better place to live and grow older in. The Decade presents a positive vision of ageing, discarding the stereotypes of diseases and disabilities and promoting focus on capacities and abilities. This approach will help to foster a more inclusive world and, consequently, care systems, which value the dignity of each individual. Although the initiative represents a resource for the global population, the Decade also provides a unique opportunity for the large community of people living with HIV in terms of increased visibility and long-term solutions for their specific ageing-related health issues. This Personal View focuses on the relevance of the Decade in improving the lives of people in the HIV community, the rationale for a stronger engagement of people living with HIV in this initiative, and the potential to reduce global disparities between the HIV community and the general population and among different global regions.
Defining the role and reach of a geriatrician
Authors: Matteo Cesari, Jotheeswaran Amuthavalli Thiyagarajan, Antonio Cherubini, Miguel Angel Acanfora, Prasert Assantachai, Mario Barbagallo, Mamadou Coume, Theresa Diaz, Nicholas Fuggle, Sonia Ouali Hammami, Kenneth Madden, Radmila Matijevic, Jean-Pierre Michel, Mirko Petrovic, Cornel Sieber, Nicola Veronese, Finbarr C Martin, Anshu Banerjee, John W Rowe
Journal: The Lancet Healthy Longevity (2024)

Population ageing is a global occurrence. Unfortunately, the shortage of health professionals with geriatric competencies is a major factor restricting high-quality care for older people worldwide. Strengthening the knowledge and skills of the health workforce to better respond to the needs of older people is a major global priority. Geriatricians can play a pivotal role in reorienting care for older people towards an integrated and person-centred care system focused on functional ability, preventive strategies, and age-friendly services. The current scenario requires efforts to be directed towards establishing a standardised competency-based definition of a geriatrician to allow for an accurate estimation of the existing workforce with adequate training in geriatrics as crucial resources to facilitate the paradigm shift. This Personal View, supported by the International Association of Gerontology and Geriatrics and the European Geriatric Medicine Society, proposes a standardised definition of a geriatrician based on expected competencies and roles and a precise description of the essential features of geriatric medicine. By reducing ambiguities and offering a competency-based framework, the current standardisation approach is expected to facilitate better support, monitoring, and allocation of resources for improving care for older people worldwide.
Enabling data linkages for rare diseases in a resilient environment with the SERDIF framework
Authors: Albert Navarro-Gallinad, Fabrizio Orlandi, Jennifer Scott, Enock Havyarimana, Neil Basu, Mark A Little, Declan O'Sullivan
Journal: npj Digital Medicine (2024)

Abstract Environmental factors amplified by climate change contribute significantly to the global burden of disease, disproportionately impacting vulnerable populations, such as individuals with rare diseases. Researchers require innovative, dynamic data linkage methods to enable the development of risk prediction models, particularly for diseases like vasculitis with unknown aetiology but potential environmental triggers. In response, we present the Semantic Environmental and Rare Disease Data Integration Framework (SERDIF). SERDIF was evaluated with researchers studying climate-related health hazards of vasculitis disease activity across European countries ( N P1 = 10, N P2 = 17, N P3 = 23). Usability metrics consistently improved, indicating SERDIF’s effectiveness in linking complex environmental and health datasets. Furthermore, SERDIF-enabled epidemiologists to study environmental factors in a pregnancy cohort in Lombardy, showcasing its versatility beyond rare diseases. This framework offers for the first time a user-friendly, FAIR-compliant design for environment-health data linkage with export capabilities enabling data analysis to mitigate health risks posed by climate change.
Corrigendum to “Increased adrenal steroidogenesis and suppressed corticosteroid responsiveness in critical COVID-19” [Metabolism volume 160 (2024) 155980]
Authors: Tian-Zi Wen, Tian-Ran Li, Xin-Yu Chen, He-Yuan Chen, Shuai Wang, Wen-Juan Fu, Shi-Qi Xiao, Jie Luo, Jia-Feng Huang, Rui Tang, Zhi-Cheng He, Tao Luo, Hong-Liang Zhao, Cong Chen, Jing-Ya Miao, Qin Niu, Yan Wang, Xiu-Wu Bian, Xiao-Hong Yao
Journal: Metabolism (2024)
Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer.
Authors: Yijun Shen, Liangju Peng, Peihang Xu, Yanhao Wang, Xiang Wang, Yao Xudong, Yushan Liu, Ding-Wei Ye
Journal: Journal of Clinical Oncology (2024)

4594 Background: In a phase I study, intravesical camrelizumab (at a maximum tolerated dose [MTD] of 200 mg) was well tolerated by patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). This phase II trial aimed to assess the efficacy and safety of intravesical camrelizumab at the established phase I MTD. Methods: Patients with histologically confirmed BCG-unresponsive high-risk NMIBC, who were ineligible for or declined radical cystectomy, received intravesical camrelizumab at a dose of 200 mg every week for up to 6 weeks as the induction course. Subsequently, the maintenance therapy started with 200 mg administered every 3 weeks and continued until reaching the maximum treatment duration of 2 years or in the event of disease progression or unacceptable toxicity. The primary endpoint was the 3-month event-free survival (EFS) rate. The secondary endpoints included 6-month EFS rate, 1-year EFS rate, recurrence-free survival (RFS), progression-free survival (PFS), and safety. Biomarker exploration included PD-L1 expression and protein sequencing. Results: Between June 2021, and December 2023, 14 patients were enrolled and received at least one dose of camrelizumab, all of whom were included in the safety analysis.At a median follow-up of 23.1 months (IQR 15.8-28.6), the median EFS was 12.68 months (95% CI 6.31-NE), with a 3-month EFS rate of 92.3% (95%CI 77.8-100), a 6-month EFS rate of 75.5% (95%CI 51.4-99.7) and a 12-month EFS rate of 50.3% (95%CI 22.1-78.6). Both median RFS and PFS was 12.68 months (95% CI 6.31-NE). Grade ≥ 3 treatment-emergent adverse events (TEAEs) occurred in 2 (14.3%) patients, one with urinary tract infection and the other with vertebrobasilar insufficiency. Serious TEAEs occurred in one (7.1%) patient. No deaths were reported. PD-L1 expression was not related to treatment efficacy. Protein sequencing revealed a total of 296 proteins with differential expression between responsive and unresponsive patients. Analysis using Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway demonstrated that the responsive group was associated with activated biological processes, including T cell receptor signaling pathway, alpha-beta T cell activation, and adaptive immune response. Conclusions: Intravesical camrelizumab demonstrated promising anti-tumor activity and acceptable tolerance in patients with BCG-unresponsive NMIBC who either declined or were ineligible for radical cystectomy. This suggests its potential as an effective non-surgical and topical treatment option for this specific population. The efficacy was attributed to enhanced immune pathway activation. Clinical trial information: NCT04706598 .